iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBioLaunch™ platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. This unique plant-based platform offers a number of significant advantages over other systems:
- Ability to synthesize complex proteins at which other systems have failed
Simplicity, scalability and flexibility
Reduced capital investment
Lower operating costs
Rapid production times – gene sequence to factory-scale protein harvest
Eliminates the need of bioreactors
Low risk of contamination by animal pathogens
iBio has a strong IP/technology portfolio and has been well established by more than nine years of applications development and $100 million in funding. Our current pipeline includes:
Interferons & cytokines
Enzymes for replacement therapy
The iBioLaunch™ platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins. The plants are easily and reliably scaled-up in low cost, controlled growth facilities to produce large amounts of recombinant protein in the plant biomass. The technology is highly flexible having the capability to produce both biotherapeutics and vaccines. Advantages of the whole plant approach include lower operating and capital expenses compared to protein production using engineered microbial or animal cells in bioreactors. The iBioLaunch platform offers significant advantages over earlier plant-based methods that rely on transgenic plants or plant cell cultures. These include the speed at which different proteins can be expressed and produced at commercial scale, which presents a significant commercial advantage, as well as public safety benefits when vaccines for pandemic diseases are required. Other advantages include scalability, no risks of contamination by animal pathogens, and the ability to express complex proteins at which other systems have failed.
The iBioLaunch technology platform addresses several multi-billion dollar markets. Its applicability to a broad range of product classes enables iBio to target global commercial collaborations in high-growth markets such as orphan biologics ($54.6 billion in 2009), biosimilars/bio-betters (~$80 billion worth of biologics sales will be susceptible to biosimilar competition, by 2013) and new proprietary biologics. The speed and superior economic scalability of the iBioLaunch™ technology make it the ideal platform for new personalized therapeutics as well as for vaccines ($32 billion in 2013).